Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.46 |
| ▸ | F2 | P00734 | 10/20 | 0.46 |
| ▸ | PLG | P00747 | 10/20 | 0.46 |
| ▸ | PLAU | P00749 | 10/20 | 0.46 |
| ▸ | PLAT | P00750 | 10/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.37 |
| ▸ | F7 | P08709 | 2/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505174 | 0.91 | HDAC6 (0.46) | F10F2PLGPLAUPLAT | |
| SCHEMBL6511666 | 0.90 | HDAC6 (0.42) | F10F2PLGPLAUPLAT | |
| SCHEMBL6510692 | 0.84 | F2 (0.47) | F10F2PLGPLAUPLAT | |
| SCHEMBL5392746 | 0.83 | F10 (0.60) | F10F2PLGPLAUPLAT | |
| SCHEMBL6530669 | 0.83 | HDAC6 (0.40) | F10F2PLGPLAUPLAT | |
| SCHEMBL6510570 | 0.82 | F2 (0.55) | F10F2PLGPLAUPLAT | |
| SCHEMBL6511656 | 0.80 | AMY1A (0.42) | F10F2PLGPLAUPLAT | |
| SCHEMBL6505463 | 0.80 | HDAC6 (0.45) | F10F2PLGPLAUPLAT | |
| Acetic Acid SCHEMBL6062185 | 0.79 | F2 (0.55) | F10F2PLGPLAUPLAT | |
| SCHEMBL6506693 | 0.78 | HDAC1 (0.48) | F10F2PLAUPRSS1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | DDT, DDC, DARS1 | F10 3872/4885F2 2666/4885PLG 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.